398 related articles for article (PubMed ID: 28122327)
1. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
[TBL] [Abstract][Full Text] [Related]
2. Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells.
Sukumar S; Wilson DC; Yu Y; Wong J; Naravula S; Ermakov G; Riener R; Bhagwat B; Necheva AS; Grein J; Churakova T; Mangadu R; Georgiev P; Manfra D; Pinheiro EM; Sriram V; Bailey WJ; Herzyk D; McClanahan TK; Willingham A; Beebe AM; Sadekova S
Cancer Res; 2017 Aug; 77(16):4378-4388. PubMed ID: 28611044
[TBL] [Abstract][Full Text] [Related]
3. Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted.
Kim YH; Shin SM; Choi BK; Oh HS; Kim CH; Lee SJ; Kim KH; Lee DG; Park SH; Kwon BS
J Immunol; 2015 Nov; 195(10):4721-9. PubMed ID: 26423152
[TBL] [Abstract][Full Text] [Related]
4. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy.
Coe D; Begom S; Addey C; White M; Dyson J; Chai JG
Cancer Immunol Immunother; 2010 Sep; 59(9):1367-77. PubMed ID: 20480365
[TBL] [Abstract][Full Text] [Related]
5. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
6. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
[TBL] [Abstract][Full Text] [Related]
7. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
[TBL] [Abstract][Full Text] [Related]
8. GITR Agonism Enhances Cellular Metabolism to Support CD8
Sabharwal SS; Rosen DB; Grein J; Tedesco D; Joyce-Shaikh B; Ueda R; Semana M; Bauer M; Bang K; Stevenson C; Cua DJ; Zúñiga LA
Cancer Immunol Res; 2018 Oct; 6(10):1199-1211. PubMed ID: 30154083
[TBL] [Abstract][Full Text] [Related]
9. Rational design of anti-GITR-based combination immunotherapy.
Zappasodi R; Sirard C; Li Y; Budhu S; Abu-Akeel M; Liu C; Yang X; Zhong H; Newman W; Qi J; Wong P; Schaer D; Koon H; Velcheti V; Hellmann MD; Postow MA; Callahan MK; Wolchok JD; Merghoub T
Nat Med; 2019 May; 25(5):759-766. PubMed ID: 31036879
[TBL] [Abstract][Full Text] [Related]
10. Rationale for anti-GITR cancer immunotherapy.
Knee DA; Hewes B; Brogdon JL
Eur J Cancer; 2016 Nov; 67():1-10. PubMed ID: 27591414
[TBL] [Abstract][Full Text] [Related]
11. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
12. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
13. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
Schaer DA; Budhu S; Liu C; Bryson C; Malandro N; Cohen A; Zhong H; Yang X; Houghton AN; Merghoub T; Wolchok JD
Cancer Immunol Res; 2013 Nov; 1(5):320-31. PubMed ID: 24416730
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
15. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid-induced TNFR-related protein stimulation reverses cardiac allograft acceptance induced by CD40-CD40L blockade.
Krill KT; Csencsits-Smith K; Wood SC; Faust S; Lu G; Bishop DK
Clin Dev Immunol; 2013; 2013():986859. PubMed ID: 23690829
[TBL] [Abstract][Full Text] [Related]
17. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.
Yang R; Sun L; Li CF; Wang YH; Yao J; Li H; Yan M; Chang WC; Hsu JM; Cha JH; Hsu JL; Chou CW; Sun X; Deng Y; Chou CK; Yu D; Hung MC
Nat Commun; 2021 Feb; 12(1):832. PubMed ID: 33547304
[TBL] [Abstract][Full Text] [Related]
18. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
Front Immunol; 2018; 9():2170. PubMed ID: 30294332
[TBL] [Abstract][Full Text] [Related]
19. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
[TBL] [Abstract][Full Text] [Related]
20. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
